Interferência dos antidiabéticos no sobrepeso: uma revisão de literatura.

Abstract

Overweight and obesity has been growing significantly worldwide, since physical exercise has been replaced by the sedentary lifestyle of new technology enthusiasts, healthy food in turn has been changed by fast food, being influenced by media and other means of communication. Both are risk factors for chronic diseases, such as type 2 diabetes mellitus, hypertension, dyslipidemias, among others. Diabetes mellitus has been worsening and becoming more prevalent. It is a disease characterized by hyperglycemia, stemming from the inability of glucose absorption by the tissues of the body, usually associated with insulin resistance. As an antidiabetic therapeutic armament, we have the following classes: Biguanides, insulin secretagogues, thiazolidinediones, α-glycosidase inhibitors, incretin and analog mimics, gliptines and amylin analogs. The treatment of diabetes mellitus, in turn, can interfere in overweight, both helping in the loss of body weight and, on the other hand, aggravating the situation causing weight gain, some of these pharmacies have properties that aid in weight loss, such as metformin, liraglutide and acarbose, on the other hand repaglinide, rosiglitazone and chlorpropamide lead to weight gain, and finally vitapliptin and pramilintide have no interference with body weight. The objective of this work was to describe the mechanisms of antidiabetic drugs and to observe their interference on body weight, through a bibliographical review of the integrative type counting with articles, monographs, dissertation and theses, of safe information portals.